Seth Lederman - Sep 28, 2021 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role
Chief Executive Officer, Director
Signature
/s/ Seth Lederman
Stock symbol
TNXP
Transactions as of
Sep 28, 2021
Transactions value $
$7,320
Form type
4
Date filed
9/28/2021, 05:04 PM
Next filing
Feb 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TNXP Common Stock, $0.001 par value Purchase $7.32K +12K +6779.66% $0.61 12.2K Sep 28, 2021 Direct
holding TNXP Common Stock, $0.001 par value 135K Sep 28, 2021 By 401(k) plan
holding TNXP Common Stock, $0.001 par value 459 Sep 28, 2021 By IRA Account
holding TNXP Common Stock, $0.001 par value 31 Sep 28, 2021 By spouse
holding TNXP Common Stock, $0.001 par value 30 Sep 28, 2021 By Leder Laboratories, Inc. F1
holding TNXP Common Stock, $0.001 par value 30 Sep 28, 2021 By Starling Pharmaceuticals, Inc. F1
holding TNXP Common Stock, $0.001 par value 205 Sep 28, 2021 By Lederman & Co., LLC F1
holding TNXP Common Stock, $0.001 par value 33 Sep 28, 2021 By L&L Technologies, LLC F1
holding TNXP Common Stock, $0.001 par value 59 Sep 28, 2021 By Targent Pharmaceuticals, LLC F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reporting person may be deemed to be a control person of this entity.